Knight Therapeutics Inc. (TSX: GUD) has fully repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders, according to a press release. The company had drawn $60 million from the facility in June 2025 to help finance its acquisition of Paladin. The repayment was funded through strong cash flow generated by its operations in Canada and Latin America, underscoring the company's robust financial health.
The revolving credit facility remains available, providing borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature subject to certain conditions. This continued access to capital supports Knight's ongoing growth strategy across its pan-American pharmaceutical business. The facility's repayment reduces the company's debt burden and interest expenses, potentially improving its net income and financial flexibility.
This development is significant because it demonstrates Knight Therapeutics' ability to generate sufficient cash flow to meet its financial obligations without needing to refinance or dilute equity. The strong operational performance in Canada and Latin America, particularly through subsidiaries like United Medical, Biotoscana Farma, and Laboratorio LKM, indicates the success of the Paladin integration and the overall business strategy. Investors may view this as a positive signal of management's discipline and the company's capacity to pursue further acquisitions or invest in growth initiatives using its available credit facility.
For more details, the full press release can be viewed at https://ibn.fm/8eluB. Knight Therapeutics is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its shares trade on the TSX under the symbol GUD. Additional company information is available at https://www.knighttx.com.
The repayment news comes as Knight continues to expand its pan-American footprint. The company's ability to repay debt quickly after a major acquisition suggests that the Paladin purchase is already generating expected synergies and cash flows. This financial maneuver positions Knight favorably for future growth, whether through organic expansion or additional strategic acquisitions. The retained borrowing capacity provides a cushion for unforeseen opportunities or market downturns, enhancing the company's risk profile.
In summary, Knight Therapeutics' repayment of the $60 million credit facility, funded by operational cash flow, highlights its strong financial performance and prudent capital management. The move reinforces confidence in the company's growth trajectory and its ability to create value for shareholders in the competitive pharmaceutical landscape of the Americas.
